anti-PLAUR antibody product blog
Tags: Antibody; Monoclonal Antibody; anti-PLAUR antibody; PLAUR; Urokinase Plasminogen Activator Receptor;
The PLAUR plaur (Catalog #MBS605397) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Urokinase Plasminogen Activator Receptor (uPAR, CD87) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s Urokinase Plasminogen Activator Receptor can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB).Suitable for use in ELISA and Western Blot.
Dilution: ELISA: 1:1000. Use as a detection antibody. Researchers should empirically determine the suitability of the PLAUR plaur for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The PLAUR plaur product has the following accession number(s) (GI #433901) (Uniprot Accession #Q03405). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Urokinase plasminogen activator receptor (uPAR), also known as CD87, is a glycolipid anchored cell surface protein consisting of three homologous domains. It binds uPA with high affinity and enhances and localizes uPA catalyzed plasminogen activation, and thereby plays a key role in cancer invasion and in several tissue remodelling processes (1-3). In addition uPAR also binds to vitronectin and may thereby have biological functions independent of its role in uPA mediated proteolysis (4,5). Elevated levels of uPAR are associated with poor prognosis in many types of cancer (2,3,6,7).
Immunogen: Native human Urokinase Plasminogen Activator Receptor (uPAR)
Culture Medium: RPMI 1640 with 10% fetal calf serum. Hybridoma: X63-Ag 8.6.5.3 myeloma cells with spleen cells from Balb/c mice. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PLAUR are readily searchable from our website. Different antibodies against the same target such as PLAUR may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. PLAUR also interacts with the following gene(s): HCK, ITGAM, PLAU. Adenocarcinoma, Breast Neoplasms, Carcinoma, Cardiovascular Diseases, Inflammation, Lung Diseases, Neoplasm Invasiveness, Skin Diseases, Urogenital Neoplasms, Vascular Diseases are some of the diseases may be linked to Urokinase Plasminogen Activator Receptor (uPAR, CD87). The following patways have been known to be associated with this gene. Blood, Bone, Brain, Embryonic Tissue, Liver, Lung, Muscle, Prostate, Skin, Vascular tissues are correlated with this protein.